MARKET

IHE

IHE

iShares US Pharmaceuticals ETF
NYSEARCA
68.63
+0.03
+0.04%
After Hours: 68.63 -0.06 -0.09% 16:00 07/25 EDT
OPEN
68.45
PREV CLOSE
68.60
HIGH
69.13
LOW
68.45
VOLUME
45.56K
TURNOVER
0
52 WEEK HIGH
69.56
52 WEEK LOW
54.77
TOTAL ASSET
669.13M
YTD YIELD
14.63%
1D
5D
1M
3M
1Y
5Y
1D
IHE: Significant Growth Ahead, But Valuation Not Cheap (Rating Downgrade)
IShares U.S. Pharmaceuticals ETF (IHE) has solid long-term growth outlook but high concentration risk. IHE's fund price has been steady with a positive trend in 2024. The fund invests in a portfolio of large-cap pharmaceutical stocks. The pharmaceuticals sector is expected to grow at a mid-single digit rate in the future. Despite its elevated valuation, IHE is a good defensive play in an economic recession.
Seeking Alpha · 1d ago
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
NASDAQ · 2d ago
Weekly Report: what happened at IHE last week (0715-0719)?
Weekly Report · 4d ago
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
NASDAQ · 07/17 10:20
ASCO Annual Meeting 2024: Breakthrough Treatments Hint At Renewed Hope For Patients And Investors
Seeking Alpha · 07/17 08:42
Weekly Report: what happened at IHE last week (0708-0712)?
Weekly Report · 07/15 12:00
Bristol-Myers Squibb's Q2 2024 Earnings: What to Expect
Bristol-Myers Squibb Company (BMY) is expected to unveil its fiscal Q2 earnings results before the market opens on Friday, Jul. 26. The biotech giant is a global leader in biopharmaceuticals. The company's shares have fallen 21.2% over the past year.
Barchart · 07/15 09:32
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
NASDAQ · 07/09 10:20
More
Profile
Fund Name
iShares US Pharmaceuticals ETF
Inception Date
2006-05-01
Benchmark
DJ US Select Pharms TR USD
Advisor Company
BlackRock Fund Advisors
Custodian
Citibank NA
Manager
Greg Savage, Jennifer Hsui, Amy Whitelaw, Paul Whitehead